MDxHealth recently reported that its third quarter revenues increased 17 percent year over year, driven by sales of its ConfirmMDx for Prostate Cancer test.

The Belgian molecular diagnostics firm reported total revenues of $4.1 million for the three months ended Sept. 30, up from $3.5 million in the third quarter of 2014.

It said that sales of the ConfirmMDx test comprised 85 percent of its Q3 revenues and case volume increased 30 percent to more than 4,500 tests compared to 3,500 tests in Q3 2014. The firm added that more than 31,000 ConfirmMDx tests, which gauges the methylation status of biomarkers associated in the published literature with prostate cancer, have been ordered since its launch in 2012.

"The strategic investments made in our managed care team during the first half of 2015, coupled with the expansion of our sales force shortly after our June capital raise have bolstered both revenue growth and adoption of ConfirmMDx for Prostate Cancer in the US," MDxHealth CEO Jan Groen said in a statement.